Whatever Johnson & Johnson ($JNJ) learned about MacroGenics’ off-the-shelf approach to stirring a T cell attack against cancer since inking their first partnership deal 17 months ago seems to have only whetted the pharma giant’s appetite for more.
{iframe}http://www.fiercebiotech.com/j-j-commits-740m-for-its-second-cancer-r-d-pact-macrogenics?utm_medium=nl&utm_source=internal&mrkid=15056235&mkt_tok=eyJpIjoiWmpaa1pqUmxZV0UxWkRkbSIsInQiOiJPVFI2eDRIZGthcERaMlRGenZodHZyd3d5bGNacmFiWXJYOEE3ZmdqSUtaVVVxR1Y3WTRYZ0lzaXpWRU1Sc3FETmpmeFF3UzM1WmpFakYzdWF1NXJ5K21XbFhxS3JvV2xxMjlRSjBwZUE5az0ifQ%3D%3D{/iframe}